Abstract
The mechanisms through which heregulin (HRG) regulates the progression of breast cancer cells to a more invasive phenotype are currently unknown. Recently we have shown that HRG treatment of breast cancer cells leads to the formation of lamellipodia/filopodia, and increased cell migration and invasiveness through the phosphatidylinositol 3-kinase (PI-3 kinase). Since the process of cell migration must involve changes in adhesion, we explored the potential HRG regulation of paxillin, a major cytoskeletal phosphoprotein of focal adhesion. We report that HRG stimulation of non-invasive breast cancer cells resulted in stimulation of p38 mitogen-activated protein kinase (p38MAPK), extracellular signal-regulated kinases (ERK) and PI-3K, and a concurrent unexpected increase in the level of paxillin phosphorylation on serine residue which was sensitive to protein-phosphatase 2b but not to protein tyrosine phosphatase 1. In addition, HRG triggered a rapid redistribution of paxillin to the perinuclear regions from the tyrosine-phosphorylated focal adhesions, and increased cell scattering. There was no effect of HRG on the state of phosphorylation and localization of focal adhesion kinase. The HRG-induced increase in serine phosphorylation of paxillin and cell scattering were selectively inhibited by a specific inhibitor of p38MAPK or a dominant-negative p38MAPK mutant, but not by inhibitors of p42/44MAPK or PI-3 kinase pathways. For the first time our results have shown that HRG, a potent migratory growth factor stimulates serine phosphorylation of paxillin. These findings suggest a role of p38MAPK-dependent signal transduction pathway(s) in serine phosphorylation and disassembly of the paxillin from the focal complexes during HRG-induced cell shape alterations and motility.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abedi H, Dawes KE and Zachary I. . 1995 J. Biol. Chem. 270: 11367–11376.
Abedi H and Zachary I. . 1997 J. Biol. Chem. 272: 15442–15451.
Adam L, Vadlamudi R, Kondapaka S, Chernoff J, Mendelsohn J and Kumar R. . 1998 J. Biol. Chem. 273: 28238–28246.
Alroy L and Yarden Y. . 1997 FEBS Lett. 410: 83–86.
Arora PD, Ma J, Min W, Cruz T and McCulloch C. . 1995 J. Biol. Chem. 270: 6042–6049.
Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J and Kumar R. . 1998 J. Biol. Chem. 273: 1568–1573.
Bellis SL, Miller JT and Turner CE. . 1995 J. Biol. Chem. 270: 17437–17441.
Bellis SL, Perotta JA, Curtis MS and Turner CE. . 1997 Biochem. J. 325: 375–381.
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM and Osborne CK. . 1993 Breast Cancer Res. and Treat. 24: 85–95.
Bergman M, Joukov V, Virtanen I and Alitalo K. . 1995 Mol. Cell. Biol. 15: 711–722.
Brown BC, Perrotta JA and Turner CE. . 1998 Mol. Biol. Cell 9: 1803–1816.
Burridge K, Chrzanowska-Wodnicka M and Zhong C. . 1997 Trends in Cell Biol. 7: 342–347.
Cano E and Mahadevan LC. . 1995 Trends in Biochem. Sci. 20: 117–121.
Chihara K, Amano M, Nakamura N, Yano T, Shibata M, Tokui T, Ichikawa H, Ikebe R, Ikebe M and Kaibuchi K. . 1997 J. Biol. Chem. 272: 25121–25127.
Deak M, Clifton AD, Lucocq JM and Alessi DR. . 1998 EMBO J. 17: 4426–4441.
De Nichilo MO and Yamada KM. . 1996 J. Biol. Chem. 271: 11016–11022.
Hall A. . 1998 Science 279: 509–514.
Hiregowdara D, Avraham H, Fu Y, London R and Avraham S. . 1997 J. Biol. Chem. 272: 10804–10810.
Hynes NC and Stern DF. . 1994 Biochim. Biophys. Acta. 1198: 165–184.
Jones FE, Jerry DJ, Guarino BC, Andrews GC and Stern DF. . 1996 Cell Growth Differ. 7: 1031–1038.
Kim H, Sierke SL and Koland JG. . 1994 J. Biol. Chem. 269: 24747–24755.
Kumar R, Shepard HM and Mendelsohn J. . 1991 Mol. Cell. Biol. 11: 979–986.
Kumar R, Mandal M, Ratzkin BJ, Liu N and Lipton A. . 1995 J. Cell. Biochem. 62: 102–112.
Leventhal PS, Shelden EA, Kim B and Feldman EL. . 1997 J. Biol. Chem. 272: 5214–5218.
Lo L, Lo SH, Wang S and Hung M. . 1999 Mol. Carcinogenesis (in press).
Ludwig S, Hoffmeyer A, Goebeler M, Kilian K, Hafner H, Neufeld B, Han J and Rapp UR. . 1998 J. Biol. Chem. 273: 1917–1922.
Marte BM, et al. 1995 Oncogene 10: 167–175.
Matsumoto K, Matsumoto K, Nakamura T and Kramer RH. . 1994 J. Biol. Chem. 269: 31807–31813.
Mazaki Y, Hashimoto S and Sabe H. . 1997 J. Biol. Chem. 272: 7437–7444.
Mitchison TJ and Cramer LP. . 1996 Cell 84: 371–379.
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB and Yarden Y. . 1992 Cell 69: 205–216.
Pinkas-Kramarski R, Shelly M, Glathe R, Ratzkin BJ and Yarden Y. . 1996 J. Biol. Chem. 271: 19029–19032.
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Segar R, Ratzkin BJ, Sela M and Yarden Y. . 1996 EMBO J. 15: 2452–2467.
Rankin S and Rozengurt E. . 1994 J. Biol. Chem. 269: 704–710.
Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanilo D, Hunt T and Nebreda A. . 1994 Cell 78: 1027–1037.
Schlaepfer DD, Hanks SK, Hunter T and Geer VD. . 1994 Nature 372: 786–791.
Seger R, Ratzkin BJ, Sela M and Yarden Y. . 1996 EMBO J. 15: 2452–2467.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. . 1987 Science 235: 177–181.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A. . 1989 Science 244: 707–712.
Stern DF, Heffernan PA and Weinberg RA. . 1986 Mol. Cell. Biol. 6: 1729–1740.
Turner CE, Glenney JR and Burridge K. . 1990 J. Cell Biol. 111: 1059–1068.
Turner CE, Schaller MD and Parsons JT. . 1993 J. Cell Sci. 105: 637–645.
Turner CE, Pietras KM, Taylor DS and Molly CJ. . 1995 J. Cell Sci. 108: 333–342.
Turner CE. . 1998 Int. J. Biochem. Cell Biol. 30: 955–959.
Vadlamudi R, Adam L, Tseng B, Costa L and Kumar R. . 1999 Cancer Res. 59: 2843–2846.
Weiner TM, Liu ET, Craven RJ and Cance WG. . 1993 Lancet 342: 1024–1025.
Yamaguchi R, Mazaki Y, Hirota K, Hashimoto S and Sabe H. . 1997 Oncogene 15: 1753–1761.
Yang Y, Spitzer E, Meyer D, Sach M, Niemann C, Hartmann G, Weidner KM, Birchmeier C and Birchmeier W. . 1995 J. Cell Biol. 131: 215–226.
Acknowledgements
We thank Stephan Ludwig for providing us with the dominant negative mutant P38AF plasmid, Mahitosh Mandal for help in metabolic labeling experiments and Ben Tseng for technical assistance in Western blots. This study was supported by the National Institutes of Health Grants CA80066 and CA65746 to R Kumar.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vadlamudi, R., Adam, L., Talukder, A. et al. Serine phosphorylation of paxillin by heregulin-β1: role of p38 mitogen activated protein kinase. Oncogene 18, 7253–7264 (1999). https://doi.org/10.1038/sj.onc.1203163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203163
Keywords
This article is cited by
-
Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth
Oncogene (2011)
-
TGFβ pathobiology in the eye
Laboratory Investigation (2006)
-
Relationship between expressions of P38 protein in human breast carcinoma and lymph nodes metastasis
Chinese Journal of Cancer Research (2006)
-
Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells
Laboratory Investigation (2005)
-
Roles for neuregulins in human cancer
Clinical & Experimental Metastasis (2005)